Yura Seo

Yura Seo

Auto-generated profile, based on publicly available information

Yura Seo

Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 FOUR Project, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
IWInbal Wortzel
Inbal Wortzel
YSYura Seo
Yura Seo
IAIfe Akano
Ife Akano
LSLee Shaashua
Lee Shaashua
GTGabriel Cardial Tobias
Gabriel Cardial Tobias
DLDavid Lyden
David Lyden

Verified
Journal Article
Open access
PDF file
YSYurin Seo
Yurin Seo
KKKyung-A Kim
Kyung-A Kim
SLSuho Lee
Suho Lee
YLYujin H. Lim
Yujin H. Lim
YSYura Seo
Yura Seo
HKHan Sang Kim
Han Sang Kim
Fusobacterium nucleatum (Fn) is increasingly recognized as a cancer-associated bacterium, yet reliable quantification in human specimens is challenging due to low bacterial burden and abundant host DNA. We analyzed 145 Fusobacterium genomes to design primers targeting conserved regions of the fadA adhesin gene and developed a duplex quantitative real-time PCR (qPCR) assay for simultaneous detection of fadA and a human PGT as an internal control. Analytical sensitivity, specificity, precision, and reproducibility were evaluated using serially diluted Fn DNA, spike-in experiments with human DNA, and cross-platform/operator validation. Clinical performance was assessed in colorectal cancer patient tissues, including fresh tissue (n = 24) and formalin-fixed paraffin-embedded (FFPE) samples (n = 22), using 16S rRNA-based methods as references. The assay successfully detected all four major Fn subspecies (nucleatum, animalis, polymorphum, and vincentii). The limit of detection was ≤0.1 pg, with no interference between duplex targets. Spike-in experiments demonstrated consistent target detection in human-DNA-rich samples, with strong linearity (R2 = 0.998) across dilutions. High precision (coefficient of variations < 5%) was observed across intra-day, inter-day, inter-instrument, and inter-operator evaluations. In fresh tissues, the assay yielded 86% sensitivity, 94% specificity, and 92% accuracy. Using the FFPE samples, the assay achieved 91% sensitivity and 100% specificity, confirming robust classification in both clinical samples. This duplex qPCR assay enables broad detection of Fn with high analytical performance in both fresh and FFPE tissues. Its simplicity, reproducibility, and compatibility with pathology workflows support deployment in multi-center studies and downstream applications in diagnostic studies and prognostic modeling.

14 April 2026 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
YSYura Seo
Yura Seo
YHYoon Dae Han
Yoon Dae Han
LBLinda Bojmar
Linda Bojmar
KKKyung‐A Kim
Kyung‐A Kim
YSYurin Seo
Yurin Seo
HKHan Sang Kim
Han Sang Kim
Early detection of colon adenocarcinoma (COAD) remains suboptimal. Fecal tests fail to diagnose 30% of stage I cancer, and serum CEA lacks sensitivity (< 40%). Extracellular vesicles (EVs) circulate systemically and package tumor‐related cargo, making them attractive non‐invasive biomarkers for cancer diagnosis. We profiled the EV proteome from 233 human patients using LC‐MS/MS, including stage I‑IV tumors with matched non‑tumor colon tissues ( n = 50 each; n = 100), paired pre‑/post‑operative plasma ( n = 90) and healthy plasma ( n = 43). Circulating EVs contained both tumor‐specific and stromal/immune cell‐derived proteins, reflecting the systemic nature of EV biology in the cancer setting. Proteomic analysis identified 745 proteins enriched in tumor‐derived EVs (e.g., SRPK1, THBS2) and 127 proteins enriched in adjacent tissues. Plasma EVs revealed 166 proteins enriched in COAD (e.g., UBA1, FCN1) and 233 enriched in healthy controls. Pathway analysis linked tumor EV cargo to angiogenesis, mRNA splicing, TGF‑ β signalling and RNA translation. Notably, a cross‐cancer comparison (pancreatic = 10, lung = 14 cases) revealed that 76% of tumor EV proteins were COAD‐specific, highlighting tissue of origin specificity. We further developed a 10‐protein EV panel comprising seven tumor‐associated and three healthy‐enriched EV proteins, which effectively distinguished COAD patients from healthy controls in the two validation cohorts ( n = 104 and n = 215), achieving > 90% sensitivity for differentiating COAD from healthy and non‐COAD colorectal conditions. Six weeks after curative resection, tumor‐associated EV proteins decreased by > 70%, whereas healthy‐associated proteins rebounded to baseline, indicating surgical responsiveness. Collectively, EV protein signatures provide a sensitive and tissue‐specific window into tumor–host communication, further supporting blood‐based early detection of COAD.

5 August 2026 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SDShani Dror
Shani Dror
IWInbal Wortzel
Inbal Wortzel
SLSerena Lucotti
Serena Lucotti
YSYura Seo
Yura Seo
JLJianlong Li
Jianlong Li
DLDavid Lyden
David Lyden
The mechanisms by which tumor-derived extracellular vesicles and particles (EVPs) promote vascular permeability during premetastatic niche formation remain unclear. Here, we show that tumor EVPs rapidly induce vascular leakiness within 1 h of administration in female mice, creating a permissive environment that enhances metastatic seeding. Rather than acting directly on endothelial cells, EVPs activate NF-κB and JAK–STAT signaling in interstitial macrophages, leading to IL-6 secretion and increased vascular permeability. Interstitial macrophage depletion markedly reduces EVP-induced vascular leakiness and metastasis. We identify extracellular vesicle-associated integrin α5 (ITGα5) as a major functional determinant of this process, promoting macrophage activation and IL-6 secretion without affecting EVP uptake. EVPs derived from colorectal cancer tumors with high ITGα5 similarly induce macrophage IL-6 secretion and vascular permeability. Together, these findings define an EVP–macrophage–IL-6 axis that drives vascular permeability during premetastatic niche formation and identify EVP-associated ITGα5 as a key mediator of metastatic progression and a potential therapeutic target.